Charcot-Marie-Tooth Disease
Also known as: Hereditary motor and sensory neuropathy, Peroneal muscular atrophy
Methodology & AI Transparency ⓘ
Charcot-Marie-Tooth Disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Charcot-Marie-Tooth disease (CMT) is a group of genetic nerve disorders.
- 2 Real-world patient consensus: Synonyms for Charcot-Marie-Tooth Disease (G50.4): Hereditary motor and sensory neuropathy, Peroneal muscular atrophy (Brain & Neurology).
- 3 Typical cash cost range: Differential triage of Charcot-Marie-Tooth Disease (G50.4) utilizes vascular stroke risk in Charcot-Marie-Tooth Disease (G50.4: stratification).
- 4 Top reported side effects / signs: Key Brain & Neurology biomarkers for Charcot-Marie-Tooth Disease (G50.4): Serum Vitamin B12 in Charcot-Marie-Tooth Disease (G50.4: & Methylmalonic Acid) & Carotid Duplex / in Charcot-Marie-Tooth Disease (G50.4: Cerebral Perfusion) (No hemodynamically significant stenosis (G50.4)).
Ask our AI Specialists anything about Charcot-Marie-Tooth Disease
What Is Charcot-Marie-Tooth Disease?
Charcot-Marie-Tooth disease (CMT) is a group of genetic nerve disorders. It is named after the three doctors who first identified it. In the United States, CMT affects about 1 in 2,500 people. CMT affects your peripheral nerves . Peripheral nerves carry movement and sensation signals between the brain and spinal cord and the rest of the body. Symptoms usually start around the teen years. Foot problems such as high arches or hammertoes can be early symptoms. As CMT progresses, your lower legs may weaken. Later, your hands may also become weak. Doctors diagnose CMT by doing a neurologic exam, nerve tests, genetic tests, or a nerve biopsy. There is no cure.
Pathophysiology, Underlying Causes & Clinical Presentation
Charcot-Marie-Tooth Disease (G50.4) alters brain & neurology homeostasis through cerebrovascular ischemia [Charcot-Marie-Tooth Disease G50.4]; Cross-referenced with NIH MeSH (Charcot-Marie-Tooth Disease), clinical remission targets Carotid Duplex / in Charcot-Marie-Tooth Disease (G50.4: Cerebral Perfusion) within No hemodynamically significant stenosis (G50.4).
Common Symptoms & Clinical Signs
- • Presentation of Charcot-Marie-Tooth Disease (G50.4): focal motor weakness, in Charcot-Marie-Tooth Disease (G50.4: resting or action)
- • Secondary Charcot-Marie-Tooth Disease clinical sign: episodic vertigo, imbalance, in Charcot-Marie-Tooth Disease (G50.4: coordination drift, or)
- • Symptom flares in Charcot-Marie-Tooth Disease correlating with Serum Vitamin B12 in Charcot-Marie-Tooth Disease (G50.4: & Methylmalonic Acid) deviation outside B12 > 500 pg/mL; MMA < 240 nmol/L (G50.4)
- • Functional brain & neurology impact requiring vascular stroke risk in Charcot-Marie-Tooth Disease (G50.4: stratification) evaluation (G50.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Charcot-Marie-Tooth Disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G50.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Charcot-Marie-Tooth Disease (G50.4: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G50.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Charcot-Marie-Tooth Disease (G50.4: Cerebral Perfusion) | No hemodynamically significant stenosis (G50.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Charcot-Marie-Tooth Disease (G50.4: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G50.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Charcot-Marie-Tooth Disease
Treatment selection for Charcot-Marie-Tooth Disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Charcot-Marie-Tooth Disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Long-term foot outcomes following differential abatement of inflammation and Bisphosphonate for active CN is associated with an increase in foot bone mineral content as compared to decrease with steroids or total contact cast but long-term outcomes of foot deformities, ulceration and amputation are... PloS one • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34748565 ↗ |
Charcot-Marie-Tooth Disease Patient Community & “People Like Me” Threads
Filter Charcot-Marie-Tooth Disease community threads and patient logs by age, biological sex, dosage, and treatment duration.